Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2025; 16(6): 107271
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.107271
Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients
Rania S Abdel Aziz, Enas M Radwan, Abdelhamid M Fouad, Mona S Abdellateif, Sally Elfishawi
Rania S Abdel Aziz, Enas M Radwan, Sally Elfishawi, Clinical Pathology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Abdelhamid M Fouad, Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Mona S Abdellateif, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Mona S Abdellateif, Basic Medical Science, Galala University, Suez 15888, Egypt
Co-first authors: Rania S Abdel Aziz and Enas M Radwan.
Author contributions: Abdel Aziz RS and Elfishawi S conceptualized the research and performed the molecular work; Radwan EM performed flow cytometry; Fouad AM performed patient management and follow-up; Abdellateif MS performed molecular work and statistical analysis. All authors wrote the and revised the manuscript according to their specialties. Abdel Aziz RS and Radwan EM contributed equally to this work as co-first authors.
Institutional review board statement: Ethical approval (No. CP2501-503-076-195) of the current study was obtained from the review board of NCI, Cairo University.
Informed consent statement: Informed consent was obtained from each patient before enrollment in the study.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at mona.sayed@nci.cu.edu.eg.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona S Abdellateif, Department of Cancer Biology, National Cancer Institute, Cairo University, 1 Fom Elkhaligue, Cairo 11796, Egypt. mona.sayed@nci.cu.edu.eg
Received: March 20, 2025
Revised: April 17, 2025
Accepted: May 16, 2025
Published online: June 24, 2025
Processing time: 93 Days and 4.2 Hours
Core Tip

Core Tip: Higher SOX11 expression correlated with FAB M2 and abnormal cytogenetics in acute myeloid leukemia (AML) patients. The association of higher SOX11 expression with the FLT-ITD mutation could be useful in identifying high-risk AML patients who may benefit from targeted or more intensive therapies. Furthermore, the association of higher SOX11 expression with cytogenetic abnormalities might have implications in predicting risk of translocation development and relapse in patients undertaking high risk therapy.